Paralel Advisors LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 13,322 shares of the insurance provider’s stock, valued at approximately $5,292,000. Humana comprises approximately 0.2% of Paralel Advisors LLC’s holdings, making the stock its 23rd biggest position.
Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in Humana by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock worth $3,652,890,000 after acquiring an additional 106,030 shares in the last quarter. BlackRock Inc. bought a new position in shares of Humana during the 2nd quarter valued at $4,138,160,000. Capital International Investors lifted its stake in shares of Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after purchasing an additional 3,097,571 shares during the last quarter. Pzena Investment Management LLC lifted its stake in shares of Humana by 34.3% in the 1st quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider’s stock valued at $948,614,000 after purchasing an additional 1,398,774 shares during the last quarter. Finally, State Street Corp boosted its holdings in Humana by 1.8% in the fourth quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock worth $1,403,877,000 after purchasing an additional 97,211 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.
Humana Stock Up 0.7%
Humana stock opened at $380.48 on Friday. The firm has a market cap of $45.69 billion, a price-to-earnings ratio of 36.00, a P/E/G ratio of 2.16 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The firm has a fifty day moving average price of $383.38 and a two-hundred day moving average price of $280.90.
Wall Street Analysts Forecast Growth
HUM has been the topic of several analyst reports. Oppenheimer reissued an “outperform” rating and set a $405.00 target price on shares of Humana in a research report on Thursday, July 30th. Zacks Research downgraded Humana from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Jefferies Financial Group raised Humana from a “buy” rating to a “buy” rating in a report on Wednesday, May 20th. Lake Street Capital initiated coverage on Humana in a research note on Thursday, July 30th. They issued a “buy” rating on the stock. Finally, Needham & Company LLC initiated coverage on Humana in a report on Wednesday, May 20th. They issued a “buy” rating for the company. Fourteen analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $395.22.
Get Our Latest Report on Humana
Humana Company Profile
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Featured Stories
- Five stocks we like better than Humana
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
